Casgevy is the first CRISPR-based therapy approved by the FDA, cleared on December 8, 2023 for patients 12 and older with sickle cell disease and recurrent vaso-occlusive crises. Vertex Pharmaceuticals sets the 2026 list price at $2.2 million for a single treatment. That price covers the drug product only. Patients also need stem cell collection (apheresis), busulfan conditioning chemotherapy, and a monthslong inpatient stay at a qualified treatment center, which pushes the estimated 2026 episode cost toward $2.8 million to $3.1 million. Because the treatment is a one-time infusion built from each patient's own edited cells, nobody buys it at a pharmacy counter, and no GoodRx coupon exists for it. Every claim runs through a hospital and a payer, usually under HCPCS code J3392 (2026).
The CMS Cell and Gene Therapy (CGT) Access Model is the biggest 2026 coverage change for Medicaid patients. CMS negotiated outcomes-based agreements with Vertex (Casgevy, $2.2 million list) and Genetix Biotherapeutics (Lyfgenia, $3.1 million list), and 32 states plus DC and Puerto Rico signed on, representing roughly 84 percent of Medicaid beneficiaries with sickle cell disease, per CMS. Under those agreements, manufacturers owe rebates to states if the therapy does not deliver agreed clinical outcomes. Beneficiaries pay nothing directly. Families should confirm their state's start date, since states joined on a rolling basis between January 2025 and January 2026. Income rules for Medicaid vary by state, so check the Medicaid income limits for your state before assuming eligibility.
Medicare and the Inflation Reduction Act play a smaller role for Casgevy in 2026. The Inflation Reduction Act of 2022 lets CMS negotiate a Maximum Fair Price for selected high-spend drugs, but Casgevy is not on the negotiated list, and a one-time inpatient gene therapy does not fit the Medicare Part D self-administered drug model. Sickle cell disease is a lifelong condition, and many adults under 65 reach Medicare through disability, so the rules for Medicare Advantage plans, which set their own prior authorization criteria, still matter. Expect the plan to demand documented recurrent vaso-occlusive crises, failed or contraindicated hydroxyurea, and treatment at a Vertex-authorized center.
What Casgevy Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same casgevy can cost many times more at a hospital than at your local pharmacy:
2026 Casgevy Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Treatment center list price (WAC, 2026) | $2,200,000 per one-time treatment (2026) | Drug product only; billed under HCPCS J3392 on a UB-04 claim. Apheresis, chemotherapy, and hospital days are billed separately in 2026. |
| Medicaid (CGT Access Model states) | $0 direct patient cost in 2026 | 32 states, DC, and Puerto Rico in the model; outcomes-based rebates paid by the manufacturer to the state. State start dates vary in 2026. |
| Commercial insurance (medical benefit) | Deductible and coinsurance up to the plan out-of-pocket maximum (2026) | Prior authorization required; most 2026 plans reach the out-of-pocket maximum in one admission. Fertility preservation is offered by Vertex to privately insured patients. |
| Medicare (Part A inpatient / Medicare Advantage) | Part A inpatient deductible $1,736 per benefit period (2026), plus plan rules | Not a Part D drug in 2026; the $2,100 Part D cap does not apply. Medicare Advantage plans apply their own prior authorization criteria. |
| Uninsured (Vertex patient assistance) | Possible free Vertex medication after enrollment (2026) | Contact Vertex Connects at 1-833-837-8395. Hospital charges for apheresis and admission are separate; ask the center about financial assistance. |
Casgevy cost by coverage type (2026). Patient cost depends on payer, state, and treatment center contract.
Source: CMS Cell and Gene Therapy Access Model (cms.gov), Vertex Pharmaceuticals, Medicare.gov 2026 costs
Why Hospitals Charge So Much
Casgevy costs $2.2 million in 2026 largely because of one-time-cure pricing logic and manufacturing complexity. Vertex argues the price is justified against a lifetime of sickle cell care, and the Institute for Clinical and Economic Review has placed its benchmark near $2.05 million. Each dose is custom made: a patient's blood stem cells are collected, shipped to a Vertex manufacturing site, edited with CRISPR/Cas9, and returned for infusion after conditioning chemotherapy. The manufacturing chain, quality controls, and limited patient population all feed the 2026 list price.
Hospital facility charges add substantially to the drug price in 2026. Treatment centers bill for apheresis, often several mobilization cycles, weeks of conditioning and neutropenic isolation, and a hospital stay that commonly runs four to six weeks. Industry estimates place these non-drug services at $700,000 to $900,000 in 2026, which is why total episode estimates reach $2.8 million to $3.1 million. Hospitals also carry the financial risk of buying the product before payment arrives, so many negotiate outcomes-based or milestone payment terms with insurers. Patients see a very different bill depending on whether the plan treats the admission as an inpatient DRG case or pays the drug separately.
HCPCS J-Codes: What Appears on Your Bill
Casgevy is billed under one HCPCS Level II code in 2026, and claims must use the institutional UB-04 (837I) format rather than a professional claim.
HCPCS J-codes for Casgevy| Code | Description | What to look for |
|---|
| J3392 | Injection, exagamglogene autotemcel, per treatment (one billable unit equals one treatment) | Confirm one unit only, effective since 01/01/2025. Duplicate units or a missing UB-04 revenue code are common causes of denial in 2026. |
Lyfgenia is billed under J3394 and Zynteglo under J3393; do not confuse them on your explanation of benefits (2026).
Source: CMS HCPCS Level II quarterly file (cms.gov); Medi-Cal CGT Access Model billing notice
Patient Assistance Programs
Uninsured patients with sickle cell disease face a 2026 cash baseline of $2.2 million for Casgevy, so no self-pay route works without help. Vertex Pharmaceuticals runs Vertex Connects Patient Support, which assigns a care manager and coordinates access, and its Vertex GPS program (1-877-752-5933) may provide free medication to eligible uninsured patients. Vertex has not published a public income cutoff as a percent of federal poverty level, so eligibility is decided at enrollment in 2026. Treatment centers may also assist with travel and lodging.
Patient assistance programs for Casgevy| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Vertex Connects Patient Support | Dedicated care manager, benefits navigation, and coordination with the treatment center (2026) | vertexconnects.com or 1-833-837-8395 |
| Vertex GPS Patient Support Program (uninsured) | Possible free Casgevy for eligible uninsured patients (2026) | 1-877-752-5933 |
| CMS Cell and Gene Therapy Access Model (Medicaid) | $0 direct cost to Medicaid beneficiaries in participating states (2026) | cms.gov/priorities/innovation/innovation-models/cgt |
Federal anti-kickback statute (42 U.S.C. § 1320a-7b) bars any manufacturer coupon or copay card from being used with Medicare, Medicaid, TRICARE, or VA coverage in 2026. Medicare and Medicaid patients should use the Medicaid CGT Access Model or their plan's own benefits, and ask Vertex Connects which support services are permitted for government-insured patients.
Source: casgevy.com/sickle-cell-disease/patient-support-program; cms.gov CGT Access Model
Medicare Part D
Medicare Part D does not typically pay for Casgevy in 2026 because the therapy is infused once during a hospital admission at a treatment center rather than dispensed by a pharmacy. Part D plans cover self-administered outpatient prescriptions, and the 2026 Part D annual out-of-pocket cap of $2,100 applies only to those covered drugs. Patients should not expect a formulary tier placement or a monthly Part D copay for Casgevy. Instead, the hospital stay is generally paid under Part A inpatient rules, with a 2026 Part A deductible of $1,736 per benefit period, while Medicare Advantage plans decide coverage and prior authorization criteria for their enrollees.
The Inflation Reduction Act does not lower the Casgevy price in 2026. CMS selects drugs for Maximum Fair Price negotiation based on Medicare spending, and Casgevy was not among the first two rounds of selected drugs. Original Medicare beneficiaries with sickle cell disease should ask the treatment center to confirm inpatient billing, any new technology add-on payment, and whether a Medicare Administrative Contractor determination is needed before admission. Beneficiaries with both Medicare and Medicaid (dual eligibles) in a participating state may access the therapy through the CGT Access Model. Ask your state Medicaid office for the start date in 2026.
Common Casgevy Billing Errors
Billing errors on a million-dollar gene therapy claim can delay payment for months, so verify these items on your 2026 explanation of benefits.
- Wrong claim form: HCPCS J3392 must be billed on a UB-04 or 837I institutional claim, not a CMS-1500 professional claim.
- Wrong code: J3394 (Lyfgenia) or J3393 (Zynteglo) billed instead of J3392 (Casgevy).
- Missing prior authorization number, leading to denial of both the drug and the inpatient stay.
- Apheresis and mobilization cycles billed as separate admissions, inflating your deductible and coinsurance in 2026.
- Out-of-network facility or professional charges at an in-network treatment center; ask for a network gap exception before admission.
Frequently Asked Questions
How much does Casgevy cost in 2026?
Casgevy lists at $2.2 million for a one-time treatment in 2026, per Vertex and CMS Cell and Gene Therapy Access Model materials. That price covers the drug only. Cell collection, conditioning chemotherapy, and the hospital stay push the estimated total episode of care to roughly $2.8 million to $3.1 million in 2026. Most patients never see that number: Medicaid in participating states charges $0 directly, and commercial plans cap your share at the plan's 2026 out-of-pocket maximum. Verify your own plan limit in your summary of benefits.
Is there a generic or biosimilar for Casgevy?
No. As of 2026 there is no generic and no biosimilar for Casgevy (exagamglogene autotemcel), and none is expected because it is a patient-specific autologous gene-edited cell therapy, not a standard drug. The FDA regulates it as a cellular gene therapy product (fda.gov). Alternatives include Lyfgenia (lovotibeglogene autotemcel, $3.1 million list in 2026), matched-donor stem cell transplant, and standard care with hydroxyurea. Ask your hematologist which fits your clinical history.
How do I apply for the Vertex patient assistance program for Casgevy?
Call Vertex Connects at 1-833-837-8395 (Monday to Friday, 8 AM to 8 PM ET) or enroll at vertexconnects.com. First, confirm the FDA label fit with your hematologist. Second, complete the enrollment form with your prescriber. Third, provide insurance details or proof you are uninsured. Fourth, if uninsured, ask about the Vertex GPS Patient Support Program at 1-877-752-5933 for possible free medication in 2026. Common denials: incomplete forms, non-authorized centers, and existing coverage.
Can I use a Casgevy savings card or manufacturer coupon with Medicare?
No. Federal anti-kickback law (42 U.S.C. § 1320a-7b) bars manufacturer coupons and copay cards for anyone with Medicare, Medicaid, TRICARE, or VA coverage in 2026. Casgevy also is not a Medicare Part D pharmacy drug, so a coupon would not apply anyway. Medicare patients should work with the treatment center on inpatient billing and Medicare Advantage prior authorization, and dual-eligible patients should ask Medicaid about the CGT Access Model.
What if my insurance denies coverage for Casgevy?
Ask for the written denial, then file an internal appeal within 60 days (Medicare and most commercial plans) with hematology records of recurrent vaso-occlusive crises and prior hydroxyurea use. Have your prescriber request a peer-to-peer review and, if needed, a step-therapy override. If the plan still denies, request external review through your state Department of Insurance or a Medicaid fair hearing. Vertex Connects and the treatment center's financial counselor can help assemble the 2026 appeal file.
Does the IRA negotiated price apply to Casgevy?
No. The Inflation Reduction Act lets Medicare negotiate a Maximum Fair Price for selected drugs, with the first prices effective January 1, 2026 and the second round effective January 1, 2027. Casgevy is not on either list, so its 2026 list price of $2.2 million is unchanged by negotiation. The 2026 Medicare Part D out-of-pocket cap of $2,100 also does not apply, because Casgevy is given during a hospital admission rather than dispensed by a pharmacy.
What does Casgevy cost without insurance at the pharmacy counter?
Nothing, because no pharmacy sells it. Walmart, Costco, Kroger, CVS, and Walgreens cannot dispense Casgevy in 2026, and GoodRx has no coupon price. Without insurance, the cash price is the $2.2 million list price plus hospital charges, which is not realistic to self-pay. Uninsured patients should contact Vertex Connects (1-833-837-8395) and Vertex GPS (1-877-752-5933) about free medication, and apply for Medicaid, since 2026 eligibility rules vary by state.
Casgevy vs Lyfgenia: which costs less and which does Medicaid cover?
Casgevy lists at $2.2 million in 2026 and Lyfgenia at $3.1 million, per CMS. Both are covered by Medicaid in states participating in the CGT Access Model, with outcomes-based rebates. Lyfgenia carries a boxed warning for hematologic malignancy, while Casgevy does not. Medical fit, not price alone, should drive the choice, so discuss both with a sickle cell specialist and confirm which therapies your 2026 plan authorizes.
